In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3% and 54.2% vs 29.2%, both p = 0.002) ⬆️common TEAEs: Npharyngitis, URTI, headache & rash #ACR23 ABSL12 @RheumNow https://t.co/T6swJgw6vE

Burden of flare & organ damage of SLE pts from the Asia Pacific cohort: Prevalence of organ damage at BL - 39% Incidence of damage accrual: ~58 per 1000PY Pts w/ >=2 flares accrued damage Flares independently⬆️risk of damage accrual #ACR23 ABST2261 @RheumNow @rheumarhyme https://t.co/nW34sI9FdP

Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel intervention is required in RA, Baker MC, #ACR23 @RheumNow https://t.co/agLtRKdDTf

Kevin. Winthrop knocks it down on WHO is immunocompromised among rheumatic disease pts at Innovation Theater ⁦@CCalabreseDO⁩ #ACR23 ⁦@alhkim⁩ ⁦@AdamJBrownMD⁩ ⁦@ELittlejohnDO⁩ https://t.co/4hFtQgvaIf

#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s